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Introduction
During the last decade, recombinant human
erythropoietin has revolutionised the management of
renal anaemia. It is highly effective in the vast
majority of patients treated, causing enhanced
erythropoiesis and a nse in haemoglobin
concentration. This has resulted not only in
amelioration of uraernic symptoms, but there has also
been objective evidence of improved quality-of-life,
exercise capacity, and cardiac function [I J. The most
striking benefits seen have been progression of left
ventricular hypertrophy which is known to account
for much of the high cardiovascular morbidity and
mortality seen in dialysis patients. and thus the
arguments for correcting renal anaemia is now
overwhelming. There is also an improvement in
nutrition following erythropoietin therapy, over and
above the improvement in appetite associated with
correction of the anaemia.
Although erythropoietin is pivotal in stimulating
erythropoiesis in patients with renal failure, it is
recognised that a number of other factors are
involved in this process. These include other growth
factors and cytokines such as stem cell factor (SCP),
interleukin-3 (lL-3), interleukin-IO (IL-lO), and
insulin-like growth factor-I (IGF-I), as well as a
large number of nutritional "ingredients" such as
iron, folic acid, vitamin B 12, vitamin B6
(pyridoxine), ascorbic acid, thyroxine, and several
trace minerals.
Poor nutrition may therefore lead to a deficiency of
one or more of these factors, causing in turn a sub-
optimal response to erythropoietin therapy. There has
also been much discussion over the last few years as
to whether it is possible to augment the response to
erythropoietin with other adjuvant therapies.
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The first adjuvant therapy to be recognised as being able
to enhance the response to erythropoieti n was
intravenous iron 12,31. Initially this was used when
patients developed either absolute or functional iron
deficiency, but it was subsequently found that lY iron
had benefits even in iron- replete patients 14,51. Other
adjuvant therapies have since been examined (table I),
and the aim of this article is to review the evidence and
potential role for these agents in the context or
erythropoietin therapy.
Table I. Metabolic adjuvant, LO cpoctin therapy.
IV iron
Folic acid
Vitamin B 12
Vitamin B6
Ascorbic acid
Vitamin D
L-carnitinc
Androgen>
IGF-I IIL-3
In considering adjuvant treatment, it is important to
distinguish between replacing a deficient substance and
administering a surfeit of a given substance. Thus, it
would appear that administration or intravenous iron has
positive effects in both iron deficiency and in iron-
replete states, whereas vitamin B 12 supplementation
will only have a positive effect if this vitamin is
deficient. In other adjuvant therapies such as carnitinc,
it is not clear whether the positive effects arc seen in
carnitine-defïcient patients, carnitinc-rcpletc patients, or
both.
IV iron
Ever since the earliest clinical studies of erythropoietin
therapy, il was observed that certain patients showing a
poor response to treatment could have this reversed with
lY iron administration 12,31. Indeed, over the last decade
it has become apparent that oral iron is largely
ineffective in this context. In both absolute iron
deficiency (when total body iron stores are
exhausted) and functional iron deficiency (when total
body iron stores are adequate but there is a failure to
release the iron rapidly enough), IV iron has proved
superior to oral iron, and there are various reasons for
this including poor absorption, poor bioavailability,
poor compliance, and the excessive demands for iron
by the bone marrow during active erythropoiesis.
Intravenous administration of iron, however, results
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in a readily available supply of iron, which can be
utilised almost immediately by the ma.rrow [6].
More recently, it has become apparent that intravenous
iron can enhance the response to erythropoietin even in
iron-replete patients. Several studies have shown an
augmented haemoglobin response and, perhaps more
importantly, significa.nt reductions in the dosage
requirements of erythropoietin (table 2) [4,5,7,8,9,10,
11,12].
Table 2. Studies of aggressive I V iron supplementation in patients receiving epoetin.
Reference No of potients % reduction in EPO dose/1'0/1 preparation
Schaefer and Schaefer (1992)7
Nyvad et al (1994)'
Al-Morncn ct al (1994)
Sundcr-Plassrnann & Hbrl (1995)"
Fishbane et al (1995)'
Macdougall et al (1996)"
Silverberg et al (1996)'0
Scpandj ct al (1996)"
Taylor ct al (1996)'2
Ahsan ct al (1996)
14
34
109
64
52
37
41
50
46
7
Gluconate
Sucrose
Sucrose
Sucrose
Dextran
Dextran
Sucrose
Dextran
Gluconate
Dextran
47%
27o/c
70'7c
46'7c
19o/c
61'70
35'7c
33%
26
Table 3. Role or adjuvant treatment in patients receiving epeerin.
Deficiencv Rep/ete References
IV iron
Folic acid
Vitamin B 12
Vitamin B6
Ascorbic acid
Vitamin I)
L- carniiinc
Androgens
IGF-I/I!.-)
\(1MCV)
X
X
x
X
X
Numerous
Pronai et al (1995 )'5
Zachee et al ( 1992)'·
Mydlik et al (1997)17
Tarng et al (1998)20
Alhitar et al (1997)24
Labonin et al (1995)2'
Ballal ct al (1991)"
Brox ct al (1996)'5. Macdougall et al (1995)"1
14
Two or these are randomiscd prospective controlled
studies, one in the correction phase of erythropoietin
therapy, and the other in the maintenance phase.
In the study by Macdougall ct a1141, 37 patients were
randemixed to receive either intravenous iron dextran
(250mg every two weeks), oral ferrous sulphate
200mg Ids, or no iron supplementation. All patients
had to have a serum ferritin greater than 100 p.gll to
be entered into this study. The patients in the IV iron
group had the best haemoglobin response (Fig. I),
maintained their serum ferritin at baseline levels, and
had the lowest erythropoietin dose requirements. In a
similar study by Fishbanc ct al lSi, patients in the
maintenance phase of erythropoietin therapy were
randorniscd to IV iron dextran (I OOmg every two
weeks) or oral iron (ferrous sulphate or iron
polyrnaltose).
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Fig. I. l lacrnoglobin response to i.v. iron (iron dextran 250 mg every
two weeks). oral iron (ferrous sulphate 200 mg t.d.s.), or no iron in 37
patients treated with r-ltuEPOI221.
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There was a significant increase in haematocrit in the
group of patients receiving IV iron, with no change in
the oral iron group (Fig. 2). The dosage requirements of
epoetin fell dramatically after two months' treatment
with IV iron.
Thus, the benefits of IV iron supplementation are
well-established in both iron-deficient and iron-
replete states.
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Fig. 2. Mean hematocrit in two groups of patients using epoetin.
Squares indicate the intravenous iron group; diamonds indicate the
oral iron group P<0.05. Taken from fishbance et al [201; used with
permission.
Folic acid
Folic acid is a low molecular weight substance which
is water-soluble. Folate deficiency in dialysis patients
is much less common than iron deficiency, but
nevertheless a number of factors make such patients
prone to this condition. These include losses of folate
during dialysis (especially high-flux haemodialysis),
poor dietary intake of folic acid due to anorexia, and
occasionally the use of drugs that interfere with folate
metabolism.
Some dialysis centres advocate the regular use of
folic acid supplementation in their patients, driven
perhaps by the conclusions of a fairly old publication
from over 30 years ago [13].
However, there is probably less dietary restriction of
folate nowadays compared to the early days of
dialysis, and the need for routine supplementation has
been questioned [14]. It is reasonable to assume,
however, that folic acid requirements will be
increased in patients treated with epoetin, and hence
III some patients a folate deficiency may be
precipitated. Pronai et al [15] reported some
resistance to epoetin in haemodialysis patients due to
folate, and a clue in this study was the presence of a
raised MeV. These patients responded to folic acid
supplementation at a dose of IOmg per day, despite
having normal plasma levels of folic acid. Generally,
measurements of red cell folate are preferable to
serum folate in terms of sensitivity and specificity.
Vitamin B12
Vitamin B 12 is also a small molecular weight substance
which can be lost during dialysis. Nevertheless, B 12
deficiency is even less common than folate deficiency,
and there is only one case report in the literature of
epoetin resistance due to B 12 deficiency which was
corrected by giving 8 12 supplementation [161. The
authors then proceeded to screen the remainder of their
dialysis population receiving epoetin, and in none of the
30 patients tested was a deficiency of 8 12 found. Thus,
although it is important to include this as a cause of
epoetin resistance, particularly if there is an unexplained
macrocytosis, there is no indication for routine 812
supplementation in patients on epecrin.
Vitamin B6
Vitamin 86 has a role in haem synthesis and in the
incorporation of iron into haem. Il is less important as a
co-factor in erythropoiesis. Vitamin 86 deficiency may
occur in dialysis patients as a result of poor dietary
intake, impaired metabolism of the active form
(pyridoxyl-S- pyrophosphate), losses in the urine
(particularly when frusernide is given), and losses in the
dialysate. As with iron and folate, it is likely that vitamin
86 requirements will be increased in patients receiving
epoetin therapy, and this may therefore precipitate a B6-
deficient state. Indeed, Mydlik et al 117J recently
reported resistance to epoetin due to B6 deficiency,
which was corrected by giving B6 supplementation. This
may be given at a dose of IOO-ISOmg per week, and it is
also important to realise that a deficiency of vitamin B6
can occur in the reel cells e1espitenormal plasma levels
of this vitamin r 171.
Ascorbic acid
A number of dialysis patients are known to develop
vitamin e deficiency, and some authors have advocated
routine supplementation in this patient group 1181.
Nevertheless, epoetin resistance due to vitamin e
deficiency has not been a problem, and the main interest
with this vitamin is whether it could have a potential role
in treating functional iron deficiency in patients with
iron overload.
This was first suggesteel by Gastaldcllo et 311191 who
treated 4 haemedialysis patients, all of whom were
receiving epoetin and who hael a functional iron
deficiency despite the presence or iron overload.
Administration of intravenous ascorbic acid improved
the response to epoetin dramatically, and the effect was
lost when the vitamin e was withdrawn (Fig. 3).
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Fig. 3. Response lO i.v. ascorbic acid in an iron-overloaded patient
receiving r-HuEPO 1271.
The response, however, was regained with further
administration of vitamin C. these observations were
put to the test in a randornised controlled prospective
study from Taiwan [20l. Tarng et al recruited 50
haemodialysis patients with functional iron
deficiency on epoetin despite high serum ferritin
levels, and they were randornised to two protocols.
each with a control group. The first protocol
consisted of intravenous iron sucrose, 1OOmg across
each dialysis for a total of 5 treatments. The second
protocol involved administering intravenous ascorbic
acid 100mg across dialysis thrice weekly for a total
of 8 weeks. The patients receiving intravenous iron
showed no response, but those given intravenous
ascorbic acid showed a significant rise in haernatoerit
and a reduction in epoetin dose requirements 1201·
The serum ferritin levels in these patients showed a
progressive fall, the transferrin saturation levels rose,
and there was a decrease in the levels of zinc
protoporphyrin. The suggested explanation for this
effect was mobilisation of iron from inert tissue
stores, or increased iron utilisation in the erythron.
Patients who may be suitable for a trial of
intravenous ascorbic acid would be those who are
showing a poor response to epoctin therapy despite
serum ferritin levels greater than 500]1 gil. Caution,
however, should be observed since it is not known
what the effect of this treatment strategy is on plasma
oxalate levels (which should be monitored) or
oxidative stress.
Vitamin ()
It has been recognised for quite some time that
secondary hyperparathyroidism can exacerbate the
anaemia associated with renal failure. Various
explanations for this have been offered including a
direct elfeet of PTH on erythroid progenitor cell
growth, and the development of bone marrow
fibrosis. More recently, this condition has also been
found to be a cause of erythropoietin resistance [21]
and again this seems to correlate with the degree of
bone marrow fibrosis. Treatment of
hyperparathyroidism by either high-dose vitamin D
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or parathyroidectomy has been shown to improve
renal anaemia even in patients not receiving epoetin
[22,23]. Again, this has been attributed to removal of
bone marrow suppression by PTH, increases in serum
erythropoietin levels, and retardation of bone marrow
fibrosis.
More recently, it has been found that high-dose one
alfacalcidol can augment the response to epoetin,
allowing reductions in dosage requirements. Two such
studies have been reported within the last couple of
years [24,25]. In the study by Albitar et al [24], 12
haemedialysis patients were given high-dose pulsed rv
alfacalcidol, and the mean haemoglobin increased from
8.7± 1.2 gldl at baseline to 10.3± 0.98 gldl at 3 months.
Goicoechea et al [25] recently published the results of a
study in 28 haemedialysis patients, 21 of whom were
receiving epoetin. The patients were treated with 2]1. g of
calcitriol intravenously after each dialysis, with
subsequent dose adjustments according to PTH, calcium,
and phosphate levels. After 12 months of treatment, 19
patients had shown a significant response with an
increase in mean haemoglobin from 10.6± 1.5 g/dl to 12.2
± 1.5 gldl (p<O.OO 1). The increase in haernatoerit in this
study correlated with the decrease in PTH leyels, and it
was therefore impossible to dissociate a.direct effect of
vitamin D from the suppression of hyperparathyroidism
[251. It is known, however, that erythroid progenitor
cells in the bone marrow do possess vitamin D receptors,
and it may be that calcitriol can stimulate the
proliferation and differentiation of such cells. This is
certainly an interesting area of research that merits
further study.
L-carnitine
Carnitine is a highly water-soluble, low molecular
weight, quartenary ammonium compound which again
can be lost across dialysis. It is an important carrier
molecule for transporting long- chain fatty acids across
the inner mitochondrial membrane, and it also appears to
be important for membrane phospholipid metabolism.
Its main physiological role is felt to be in skeletal and
cardiac muscle metabolism. Many of the symptoms of
carnitine deficiency are due to depletion of carnitine
stores in both cardiac and skeletal muscle, and improved
energy and cardiac function have been reported
following carnitine supplementation [26]. Ideally,
carnitine deficiency should be diagnosed by a muscle
biopsy, but it is possible to measure carnitine levels in
the blood. In this context, both free and acyl eamitine
can be measured, and carnitine deficiency is often
reported to be present when the acyl carnitine (AC) to
free carnitine (FC) ratio is greater than 0.4.
A role for carnitine has also been found in stabilising lhe
red cell membrane. Thus, it is important for red cell
survival, and the life-span of the red cell population may
be reduced in carnitine-deficient states. Therefore,
although carrutme is not directly implicated in
erythropoiesis, it seems to have a role in maintaining the
natural life-span of the red cell population.
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In recent years, there has been some interest in the role
of carnitine in patients receiving epoetin therapy.
Kooistra et al [27] showed that the response to epoetin
correlated with blood carnitine levels, with carnitine -
deficient patients requiring the highest doses of epoetin.
This led to the hypothesis that giving supplementary
carnitine might augment the response to epoetin, and
this has been the subject of several studies. The most
widely quoted of these is the one by Labonia [28], in
this study, patients received either L-carnitine or
placebo for a period of 6 months. No change in
epoetin dose requirements was seen in the placebo
group, but the patients given L- carnitine had a 38%
reduction in epoetin dose compared to baseline (p <
0.02) (Fig. 4).
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Fig. 4. Effect of 6 month, of treatment with L-carnitinc or placebo
on r·HuEPO dose requirrnents 1281.
ln this study, there was no detectable change in red
cell osmotic fragility or endogenous epoetin
secretion. A study by Matsumura et al [29],
however, confirmed a correlation between epoetin
dose and free carnitine levels, in addition to showing
irrcreased red cell osmotic fragility in patients with a
ldw L-carnitine level. Aclministration of L-carnitine
has also been found to reduce erythrocyte membrane
fragility in dialysed patients [30[. As with vitamin D
supplementation, further controlled studies of
carnitine supplementation are required before the
exact role of this treatment strategy can be
elucidated.
Androgens
It has been recognised for several decades that
androgens promote erythropoiesis, and this was put
to therapeutic use in the 1970 before epoctin therapy
was available. Dialysis patients often showed an
improvement in their anaemia with anclrogen
supplementation, although the treatment tended to be
effective in mild cases only. There are two suggested
mechanisms for this effect: (I) androgens can
enhance endogenous erythropoietin production; and
(2) androgens may increase the sensitivity of
erythroid progenitor cells to erythropoietin [31 J.
With the advent of epeerin therapy in the late 1980.
several workers investigated whether androgens
could potentiate the effect of epoetin in dialysis
patients [31,32[. One of the earlier studies involved
treating 15 adult male haemedialysis patients with
epoetin 2000 units thrice weekly, with or without the
addition of 100mg nandrolone decanoate
intramuscularly each week [31 [. After 12 weeks of
therapy, the haernatoerit had increased slightly in the
group receiving cpoetin alone (25.3% to 27.4%), but
there was a much more marked response in the group
receiving combination therapy (24.4% to 32.9%; p <
0.00 I vs. epoetin alone).
In a longer-tenn study, Gaughan et al [32[ treated II
male and 8 female patients on haemedialysis.
One group received epoetin alone (1500 units thrice
weekly for 6 months), and the other group received the
same dose of epoetin along with nandrolone dccanoate
IOOmg intramuscularly each week. Both groups showed
significant increases in mean haernatoerit levels
compared with baseline, but there was a much greater
increase in the androgen-treated group compared with
the group receiving epoetin alone (8.2% vs. 3.5%;
p=O.O12). Not all studies, however, have shown a
posiuve effect of androgen supplementation. ln a
controlled study by Berns et al [331, no difference in the
response to intravenous epoctin (120 U/kglweek) was
seen with the addition of intramuscular nandrolonc
decanoatc 2mg/kg/week over a 16-week period.
There are two concerns about using androgen adjuvant
therapy. The first is the high incidence of side-effects,
including virilisation, hirsutism, voice changes, acne,
cholesiasis, and hepatic damage. There is also a concern
that androgens may increase the risk of prostatic
carci noma, and for this reason some authors have
recommended that the use of androgens be confined lO
men aged over 50 years. There has, however, been much
interest in the potential role of androgens in augmenting
the response to epoetin in countries with limited
financial resources. Cost-benefit studies have not been
performed, but it is possible that the combination of low-
dose epecrin and androgen therapy may be cheaper than
using epecrin alone.
Other cytokincs / growth factors
Although erythropoietin is the major regulator of red cell
production, a number of other cytokines and growth
factors arc known to be involved in this process. Some
of these act at an early stage of red cell differentiation,
such as stem cell factor and interleukin-3, and a role for
other factors such as interleukin-IO and insulin-like
growth factcr-I has also been identified. [nsulin-like
growth factor-I has been known to stimulate
erythropoiesis since 1982 [341. Erythroid progenitor
cells possess IGF-I receptors, and il is via this
mechanism that growth hormone can exert its effect on
erythropoiesis.
Brox et al [35] have studied the use of IGF- I as an
adjunct to epoetin in 5/6 nephrectornised mice.
The animals were given sub-therapeutic doses of
cpnerin. IGF- I, or the combination of the two.
Neither epoetin or rGF-1 on its own caused any
significant change in haemoglobin, but the
combination resulted in correction of anaemia in the
majority of mice treated. Indeed, the response to
combination therapy was similar to that seen with the
maximal dose of epoetin in a dose-finding study [35].
These results suggest that the combination of epoetin
and [GF- I could be beneficial in renal patients, but
no human studies are as yet avai lable.
Similarly, interleukin-3 is known to potentiate
erythropoiesis, and indeed a deficiency of this
cytokine has been suggested as a cause of epoetin
resistance [361. [nterleukin-3 acts by increasing the
number of colonies derived from BFU-E which
results in an expansion of the erythroid progenitor
cell pool (37). In vitro studies in patients with renal
anaemia receiving epoetin therapy showed enhanced
growth of BFU-E when lL-3 was added to the culture
medium [381. An in vivo study has also shown
potentiation of lL-] on erythropoiesis [39]. In this
latter study, rabbits were rendered uraemic and
anaemic by 5/6 nephrectomy; one group was then
treated with epoetin alone while the other group
received epoetin plus interleukin-3. The latter group
showed a greater increase in haemoglobin
concentration over the next 2-3 weeks 139].
Conclusions
Thus, it is clearly possible to potentiate the response
to epoetin by co-administering other agents.
In some instances, this response is seen when there is
a deficiency of a certain substance. In other cases,
administration of an adjuvant such as IV iron,
vitamin D, L-carnitine, or androgens can enhance the
response to opoerin when given as a surfeit. The role
of the various adjuvants described in this paper i~
summarised in table 3 in relation to both deficiency
and replete states. With most of these agents, with
perhaps the exception of intravenous iron, further
research is required lo determine the exact role they
may play in clinical practice. As long as the cost of
cpoctin therapy remains fairly high, the challenge
will continue as to the best way of optimising its
effect, and we can look forward 10 new dcvclopmcnrs
in this expanding area of research.
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